If the directors are really interested in promoting the services and technology for personalised medication, they should start to look for opportunities in China market. they should find a good china market consultant to carry out the jobs for them as they are proving hopeless over the years in terms of promoting the PYC technology platforms and unique services. although they signed up certain clients including major global pharmaceutical companies but the clients base and usage volume should be much wider and higher.
China is expected to soon announce a massive investment in precision medicine, with plans to spend $9 billion over the next fifteen years. The effort will combine genomic sequencing and clinical patient data to tailor medical treatments to individuals, with the goal of improving care and curtailing waste. China's investment dwarfs a similar US initiative. One year ago, the US announced a $215 million plan, run by the National Institutes of Health, though that effort was spread over just four years. Some of China's money will be allocated to develop new drugs, based on research discoveries. - See more at: http://www.chinabiotoday.com/articles/20160202#sthash.KLMzRyyH.dpuf
Hi Draey, good to see you're back here. SAR looks good, but VAL (the mm's) are playing very well the game there. Also, YA Global is killing the share price & performance. Here, We know already, no news, lack of communication from our BOD sink your price. I wonder what's they done or they will do with £990k from last Year. Have a good day out there Mate, take care. Obelix
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.